Cellosaurus logo
expasy logo

Cellosaurus PC-3 [Human lung carcinoma] (CVCL_S982)

[Text version]
Cell line name PC-3 [Human lung carcinoma]
Synonyms PC-3; PC3; JPC-3; PC3JPC3
Accession CVCL_S982
Resource Identification Initiative To cite this cell line use: PC-3 [Human lung carcinoma] (RRID:CVCL_S982)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
From: Immuno-Biological Laboratories (IBL); Tokyo; Japan.
Population: Japanese.
Doubling time: 41.7 hours (PubMed=8286010); ~90 hours (Note=Lot 01072008), ~45 hours (Note=Lot 09302011), 2-4 days (Note=Lot 07162019) (JCRB=JCRB0077).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
Sequence variations
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.27
Native American0
East Asian, North77.82
East Asian, South20.28
South Asian0
European, North0
European, South1.63
Disease Lung adenocarcinoma (NCIt: C3512)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 48Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=1240202; JCRB=JCRB0077

Markers:
AmelogeninX
CSF1PO12,15
D5S81812
D7S82011,13
D13S31711,12
D16S53910
TH019
TPOX8
vWA14

Run an STR similarity search on this cell line
Publications

PubMed=1847845; DOI=10.1007/BF00685110
Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Ohmori T., Saijo N.
Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Cancer Chemother. Pharmacol. 27:263-270(1991)

PubMed=8286010
Kiura K., Watarai S., Shibayama T., Ohnoshi T., Kimura I., Yasuda T.
Inhibitory effects of cholera toxin on in vitro growth of human lung cancer cell lines.
Anticancer Drug Des. 8:417-428(1993)

PubMed=8263009; DOI=10.1007/BF01202192
Kashii T., Mizushima Y., Monno S., Nakagawa K., Kobayashi M.
Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.
J. Cancer Res. Clin. Oncol. 120:143-148(1994)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9673367
Fujishita T., Mizushima Y., Kashii T., Kobayashi M.
Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Anticancer Res. 18:1537-1542(1998)

PubMed=10358721; DOI=10.18926/AMO/31626
Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K., Kohara H., Harada M.
Establishment of a drug sensitivity panel using human lung cancer cell lines.
Acta Med. Okayama 53:67-75(1999)

PubMed=10536175; DOI=10.3892/ijo.15.5.927
Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.
Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.
Int. J. Oncol. 15:927-934(1999)

PubMed=11005564; DOI=10.1038/sj.neo.7900094; PMCID=PMC1550293
Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M., Yokota J.
Mutation and expression of the DCC gene in human lung cancer.
Neoplasia 2:300-305(2000)

PubMed=15999539
Matsumura T., Takigawa N., Kiura K., Shibayama T., Chikamori M., Tabata M., Ueoka H., Tanimoto M.
Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.
In Vivo 19:717-721(2005)

PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331
Nagai Y., Miyazawa H., Hu Q., Tanaka T., Udagawa K., Kato M., Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Cancer Res. 65:7276-7282(2005)

PubMed=19472407; DOI=10.1002/humu.21028; PMCID=PMC2900846
Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
A gene-alteration profile of human lung cancer cell lines.
Hum. Mutat. 30:1199-1206(2009)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x; PMCID=PMC11158680
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Cancer Sci. 101:1891-1896(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) JCRB; JCRB0077
Cell line databases/resources CLO; CLO_0037036
cancercelllines; CVCL_S982
Cell_Model_Passport; SIDM00361
Cosmic-CLP; 1240202
DepMap; ACH-002184
LINCS_LDP; LCL-1664
Biological sample resources BioSample; SAMN03471064
Chemistry resources GDSC; 1240202
PharmacoDB; PC3_JPC3_1249_2019
Encyclopedic resources Wikidata; Q54938404
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM827580
GEO; GSM1670340
Polymorphism and mutation databases Cosmic; 801572
Cosmic; 844833
Cosmic; 876135
Cosmic; 917973
Cosmic; 929150
Cosmic; 932923
Cosmic; 946056
Cosmic; 1154599
Cosmic; 1239894
Cosmic; 1571734
Cosmic; 1995465
Cosmic; 2125283
Cosmic; 2668305
IARC_TP53; 2384
Progenetix; CVCL_S982
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation03-Feb-2014
Last entry update19-Dec-2024
Version number32